Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Will FTC Shakeup Impact Pharma?

Feb 12 2018

• By Brenda Sandburg

United States Federal Trade Commission building in Washington, DC

Related Content

FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene

Jun 20 2014

Pay-For-Delay Settlements Decline In Wake Of Supreme Court Ruling

Nov 02 2017

Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition

Nov 09 2017

FTC Scrutiny Of Profit Seeking In Drug Supply Chain In Fact-Finding Mode

Nov 24 2017

Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits

Jun 24 2013

Biosimilar/Brand Patent Settlements Need US Antitrust Review, PBM Says

Feb 07 2018

FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions

Feb 09 2017

FTC Focus On Pay-For-Delay Deals Continues; Endo Agrees To 10-Year Abstention

Jan 25 2017

FTC Faces Uphill Battle In AndroGel Pay-For-Delay Suit

Sep 14 2015

Related Companies

Allergan plc

AbbVie Inc.

Amgen, Inc.

Express Scripts Holding Company

Solvay SA

Teva Pharmaceutical Industries Ltd.

Perrigo Company PLC

Allergan plc

Amneal Pharmaceuticals, Inc.

Endo, Inc.

Takeda Pharmaceutical Co. Ltd.

Bristol Myers Squibb Company

Viatris Inc.

Indivior plc

Additional Topics

United States FDA Intellectual Property Policy BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window